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Background: Although gene testing is widely available for Hypertrophic Cardiomyopathy (HCM), determining the clinical implications 
of a mutation is limited by an understanding of its phenotype. Inbred populations with founder mutations provide an opportunity to study 
genotype-phenotype correlations.
methods: We recruited 28 Lebanese families with HCM. Index patients from 20 families received targeted sequencing for a panel of 
sarcomere protein genes including TNNI, and 7 families received Sanger sequencing for the TNNI gene.
results: We identified a missense mutation R21C in the TNNI gene segregating with HCM in four families from South Lebanon (14.3% of 
the total Lebanese cohort and 67% of the South Lebanon cohort). Also 504 control subjects from Lebanon tested negative for the R21C 
mutation (OR>84, p-value<0.0001). Through cascade screening, we identified 30 patients from the four families that are heterozygous for 
the TNNI R21C mutation. Twenty (67%) of them had a clinical diagnosis of HCM with a median age of 37 years, while 9 (30%), with median 
age 21 years, had no evidence of HCM on echocardiography. An additional 27 members of the families had evidence of HCM, including 
22 with SCD in the setting of no past medical history, and their carrier status for R21C was implied from the pedigrees. Survival analysis 
for 57 HCM patients with the mutation revealed a markedly decreased age at first adverse event as compared to 47 HCM patients with the 
MYBPC3 R502W mutation. Additional phenotyping of selected members showed cardiomyocyte disarray on autopsy heart of patient who 
had SCD in the absence of hypertrophy, as well as suggestive findings on myocardial tissue Doppler and cardiac MRI in genotype positive 
patients with a normal echo.
conclusion:  Founder mutations in HCM that cause a severe phenotype are uncommon. The R21C mutation in TNNI is the first HCM 
mutation described in the Lebanese population and has a founder effect in South Lebanon. The R21C mutation in TNNI is associated with 
severe cardiac hypertrophy and/or sudden deaths at a young age. Early and more frequent screening with different imaging modalities as 
well as tailored management might be warranted for carriers of this mutation.
